Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Iomega Thread without Iomega -- Ignore unavailable to you. Want to Upgrade?

To: sheila rothstein who wrote (1413)	9/7/1998 2:09:00 PM
From: Dale Stempson	Respond to of 10072

Herb Greenberg >>> Could someone dig up Herbie GEE's post where he recommended SYQT's Sparq over Jaz. I would like to send him a friendly Email about it. He and I have an ongoing battle about IOM where he's recommending taking 2 ASA's and calling him in the morning. SR <<< Sheila, as my young daughter would say, "Go Girl!" HG published most of his comments about Iomega and SyQuest while he was writing for the SF Chronicle. Their site is: sfgate.com You can do a search on "SyQuest" and read through his past writings. Note: you must do an "Article" search by year, (not a "FastFind" type search). Regards - Dale

To: sheila rothstein who wrote (1413)	9/8/1998 2:46:00 AM
From: Reseller	Read Replies (1) \| Respond to of 10072

Herb on Syquest thestreet.com. The Scoop on Syquest Iomega (IOM:NYSE) rival Syquest (SYQT:Nasdaq) has never been able to dig itself out from under. However, now with Iomega stumbling, Syquest is finally starting to get attention, in part because of the success of its SparQ drive. Yet you wouldn't know it from Syquest's stock, which aside from yesterday's heavy volume has generally languished since the SparQ's rollout. Investors have been turned off, in part, by the number of Syquest shares outstanding. On paper, there are 72 million shares. But what's really frightening is that another 100 million or so are in the form of warrants that Syquest gave in recent years to suppliers and others as a way to get them to give the company a second chance. Investors have worried that once those warrants are exercised the dilution from so many shares will overshadow any improvement the company may eventually show. So, why would anybody own the stock? One large Syquest holder, very much a not-for-attribution type, told me Wall Street's mistake is not factoring in the cash Syquest will get when and if the warrants are exercised. He figures it'll be in the range of around $250 million. And with 170 million shares outstanding, even at today's price of around $3 Syquest's market value will be just $500 million -- "just,'' that is, when you compare it with Iomega's $2 billion. Both companies are expected to post losses this quarter. The difference is that while Iomega's business appears to be getting worse, Syquest's appears to be getting better.